Strontium ranelate 135459-87-9 CAS NO.135459-87-9

Min.Order Quantity:: 1 Kilogram

Purity:: 99%

Port:: China Main Port

Payment Terms:: L/C,T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

Strontium ranelate
135459-87-9
Strontium ranelate

Quick Details

ProName: Strontium ranelate 135459-87-9
CasNo: 135459-87-9
Molecular Formula: 135459-87-9
Appearance: NA
Application: Inorganic Chemicals
DeliveryTime: With about 7-10 days after receipt the...
PackAge: 1KG -200KG Drum with pallet
Port: China Main Port
ProductionCapacity: 1 Metric Ton/Week
Purity: 99%
Storage: NA
Transportation: by air
LimitNum: 1 Kilogram
Grade: Industrial Grade,Pharma Grade

Superiority

competitive price

high quality

fast delivery

custom-made

welcome to henan tianfu chemical co., ltd. website. our company engages in sodium tripolyphosphate (stpp) and sodium hexametabphosphate (shmp) production; development of noble metal catalysts, synthesis of electronic chemical materials and general chemicals imp&exp trading business. the company is located in zhengzhou high-tech development zone with import and export license. we passed iso 9001:2008 in 2009, and won "high-tech enterprise" by provincial government in 2013. our stpp and shmp has reached an annual output of 30000 tons and has successfully passed sgs, ciq audits on many occasions.

in 2011 we entered the fine chemical market of noble metal catalyst ,organic phosphine ligands and oled intermediates.with the joint efforts of our senior experts and professional technicians, tianfu has developed more than 500 compounds, which are widely used in the fields of production and life science. the objective of the company is to put quality first and put our customer’s needs first - the satisfaction of our customers is the company's ultimate goal. improving product quality and service level is our responsibility, and creating more value for our customer’s is our purpose. we are constantly striving to make henan tianfu a leading chemical supplier, and hope to create a better future with you.

Details

strontium ranelate basic information

drug for the treatment of osteoporosis application

product name:	strontium ranelate
synonyms:	distrontium renelate;5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid strontium salt (1:2);strontium ranelate;5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic acid strontium salt;protelos;protos;s 12911;s 12911-2
cas:	135459-87-9
mf:	c12h6n2o8ssr2
mw:	513.491
einecs:
product categories:	all inhibitors;inhibitors;intermediates & fine chemicals;pharmaceuticals;pharmaceutical intermdiate;api;other apis
mol file:	135459-87-9.mol

strontium ranelate chemical properties

mp	>310°c (dec.)
storage temp.	-20°c freezer

safety information

hazard codes	xn
risk statements	20/21/22
safety statements	36/37

msds information

strontium ranelate usage and synthesis

drug for the treatment of osteoporosis	strontium ranelate is a drug for the treatment of osteoporosis with its appearance being white to light yellow powder or crystalline powder. it is odorless and slightly soluble in water but almost insoluble in ethanol and easily soluble in dilute hydrochloric acid. it was first studied and developed by the french servier company and had first entered into market in november 2004 in ireland and entered into market in uk in december of same year. japan's fujisawa pharmaceutical company has owned the authorization of development, production and marketing right of this product in japan. it is clinically mainly used for the treatment and prevention of osteoporosis in postmenopausal women with significantly reducing the risk of occurrence of vertebral fractures and hip fractures. strontium ranelate has dual pharmacological inhibitory effects of both inhibiting bone absorption and promoting bone formation. on the one hand, in the osteoblast-enriched cells, it can increase the synthesis of collagen and non-collagen proteins and promote the osteoblast-mediated bone formation mediated by osteoblasts through enhancing the proliferation of pre-osteoblast. on the other hand, through decreasing the osteoclast differentiation and reabsorbing activity and further reduction of bone absorption, it achieves the rebalance of bone turnover, further boosting the bone formation. strontium ranelate mainly exerts its pharmacological effects through its strontium atoms. strontium is an alkaline earth metal element which is cognate with calcium and located under the calcium in the element periodic table. its absorption, distribution, excretion is similar with calcium. after oral administration of 2g, the absolute bioavailability of strontium is 27%. large doses of strontium cause abnormalities of bone mineral metabolism with low doses of strontium being able to the enhance the pre-osteoblast replication, increasing the number of osteoblasts to stimulate bone formation while reducing the activity of osteoclasts, reducing osteoclast quantity as well as reducing the rate of bone absorption. the results are consistent with the results found in animal and human in vivo studies. s (op) is a progressive skeletal disease, characterized by reduced bone mineral density (bmd) and degenerative changes in bone tissue microstructure. it is exhibited as bone fragility and fracture-prone with the latter most commonly happening in the spine, hip and wrist. for women, when after surgical removal of the ovaries or menopause, the body stops producing bone to maintain strong estrogen, thus, primary op is particularly common in post-menopausal or menopausal women. there are currently two major kinds of drugs used in the treatment of osteoporosis: one kind includes those drugs that inhibits osteoclast activity and therefore inhibiting bone absorption such as bisphosphonates, estrogen and calcitonin; the second category includes those drugs which promote the osteoblast activity, and thereby stimulating bone formation and there are currently only a product, human recombinant parathyroid hormone 1-34, that has entered into market. it however requires injection with high drug prices. the above information is edited by the chemicalbook of dai xiongfeng.
application	it is mainly used for the treatment and prevention of osteoporosis in postmenopausal women and significantly reduces the risk of occurrence of vertebral fractures and hip fractures.
chemical properties	crystalline solid
usage	bone metabolism modulator; inhibits bone resorption while maintaining bone formation. antiosteoporotic
usage	strontium ranelate (protelos) is a strontium(ii) salt of ranelic acid for (-)-desmethoxyverapamil binding to calcium channel with ic50 of 0.5 mm.